Aminopterin/methotrexate embryofetopathy

Aminopterin/methotrexate embryofetopathy (also known as fetal aminopterin syndrome or methotrexate embryopathy) is a rare congenital disorder caused by prenatal exposure to aminopterin or methotrexate, which are folic acid antagonists. These medications, used as antineoplastic agents or immunosuppressants, act by inhibiting dihydrofolate reductase, thereby disrupting folate metabolism critical for normal embryonic and fetal development. Exposure during the first trimester of pregnancy, particularly between weeks 6 and 8 of gestation, carries the highest risk for structural malformations. The condition affects multiple body systems. Key clinical features include craniofacial abnormalities such as craniosynostosis (premature fusion of skull bones), wide fontanelles, a broad nasal bridge, micrognathia (small jaw), and cleft palate. Limb anomalies are common, including short limbs, absent or hypoplastic digits, and talipes (clubfoot). Skeletal defects may involve vertebral and rib anomalies. Central nervous system involvement can lead to intellectual disability and neural tube defects, including anencephaly and meningomyelocele. Growth restriction, both prenatal and postnatal, is frequently observed. Some affected pregnancies result in spontaneous abortion. There is no specific cure or targeted treatment for aminopterin/methotrexate embryofetopathy. Management is supportive and symptomatic, involving a multidisciplinary team including geneticists, orthopedic surgeons, craniofacial specialists, neurologists, and developmental therapists. Surgical correction may be required for craniosynostosis, cleft palate, or limb deformities. Prevention is the most important strategy: methotrexate is strictly contraindicated during pregnancy, and women of childbearing age taking methotrexate are counseled to use effective contraception and discontinue the medication well before conception. Folic acid supplementation is recommended when discontinuing methotrexate prior to planned pregnancy.

Common questions about Aminopterin/methotrexate embryofetopathy